Skip to search formSkip to main contentSkip to account menu

pridopidine

Known as: 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine, huntexil, 4-(3-methanesulfonylphenyl)-1-propylpiperidine 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Piperidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Design and synthesis of bridged piperidine and piperazine isosteres.
2018
2018
Effects of the Dopamine Stabilizer, Pridopidine, on Basal and Phencyclidine-Induced Locomotion: Role of Dopamine D2 and Sigma-1 Receptors.
BACKGROUND Pridopidine, a compound in clinical trials for Huntington's disease treatment, was originally synthesized as a… 
2017
2017
Biological Insights of the Dopaminergic Stabilizer ACR16 at the Binding Pocket of Dopamine D2 Receptor.
The dopamine D2 receptor (D2R) plays an important part in the human central nervous system and it is considered to be a focal… 
2017
2017
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
BACKGROUND Open-HART is an open-label extension of HART, a randomized, placebo-controlled, dose-ranging, parallel-group study… 
2015
2015
Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
Huntington disease (HD) is a chronic, genetic, neurodegenerative disease for which there is no cure. The main symptoms of HD are… 
2015
2015
The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
Aim Pridopidine, a new oral drug for treatment of patients with motor symptoms associated with Huntington's Disease (HD) is… 
2012
2012
The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans
The influence of the cytochrome P450 enzyme CYP2D6 in the metabolism of the novel dopaminergic stabilizer pridopidine was… 
2012
2012
Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing
Pridopidine is being developed for the treatment of impaired motor function associated with Huntington’s disease and belongs to a… 
2011
2011
Pridopidine in treatment of Huntington's disease: beyond chorea?
Highly Cited
2006
Highly Cited
2006
The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy…
“Dopamine stabilizers” are a new class of compounds that have the ability to reverse both hypo- as well as hyperdopaminergia in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)